May 08, 2026 | Read online

Now Live: (MBRX) Just Lit Up Our Morning Radar

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

Market Maven Insights Puts (NASDAQ: MBRX) #1 On Today’s Watchlist—Friday, May 8, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Check Out (MBRX) Right Now…

May 8, 2026
Now Live: (MBRX) Just Lit Up Our Morning Radar

Dear Reader,

In oncology biotech, some of the biggest shifts begin quietly.

Not with a single breakthrough headline.
But when multiple developments start aligning at the same time, clinical progress, regulatory advancement, expanding research activity, and growing industry attention.

That’s the type of setup beginning to form around Moleculin Biotech, Inc. (Nasdaq: MBRX).

Over the past several months, the company has continued advancing across multiple high-need can-cer indications through a pipeline centered around targeted therapies and ongoing collaborations with established research institutions. As additional milestones approach, the broader clinical picture has started becoming more defined.

Early findings have shown encouraging signs, while existing regulatory designations continue supporting development efforts across key oncology programs.

At the same time, visibility around the story appears to be growing.

That’s why Moleculin Biotech, Inc. (Nasdaq: MBRX) has rapidly climbed toward the top of our watchlist this morning—Friday, May 8, 2026.

From a structural perspective, the setup also remains notable. With fewer than 6M shares currently in the public float, (MBRX) within an exceptionally tight structure where even moderate increases in attention can lead to amplified movement.

And with multiple upcoming milestones still ahead, this remains a company that could continue drawing broader visibility as momentum builds.

Analyst Coverage Suggests Significant Upside Potential

Recent coverage from multiple research firms has placed (MBRX) on the radar, with targets that point to a wide range of potential upside from current levels.

Several analysts have issued or reiterated targets that reflect triple-digit percentage ranges based on recent pricing.

H.C. Wainwright analyst Sara Nik currently maintains a $22 target on (MBRX), implying potential upside of roughly 800% from recent levels near the mid-$2 range.
Maxim Group’s Jason McCarthy, Senior Managing Director and Head of Biotechnology Research, currently maintains a $20 target on (MBRX), implying potential upside of roughly 700%–800% from recent levels.
Roth MKM analyst Jonathan Aschoff currently maintains a $31 target on (MBRX), implying potential upside of more than 1,100% from recent levels.

Inside Moleculin Biotech’s Expanding Oncology Pipeline

Moleculin Biotech, Inc. (Nasdaq: MBRX) is a late-stage pharmaceutical company focused on developing therapies targeting hard-to-treat cancers and viral diseases. The company’s pipeline is centered around next-generation oncology treatments designed to address areas with significant unmet medical need, particularly where existing therapies face limitations tied to toxicity, resistance, or treatment durability.

Current programs and product candidates include:

Annamycin (Naxtarubicin): Moleculin’s lead dr-ug candidate and a next-generation anthracycline designed to avoid multidr-ug resistance mechanisms while potentially reducing the cardiotoxicity commonly associated with traditional anthracycline chemotherapy dr-ugs. Annamycin is currently in late-stage development for relapsed/refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases through the company’s global Phase 2B/3 MIRACLE trial. The therapy has received FDA Fast Track and Orphan dr-ug designations in AML, along with Orphan designation from the EMA.
WP1066: An immune/transcription modulator designed to inhibit p-STAT3 and other oncogenic transcription factors while also stimulating anti-tumor immune responses. WP1066 is being explored across multiple difficult-to-treat cancers, including pediatric brain tumors, glioblastoma, pancreatic cancer, and other solid tumors. Recent Phase 1 data in pediatric recurrent malignant brain tumors demonstrated encouraging immune response activity and safety signals supporting further development.
WP1122 Portfolio: A group of antimetabolite compounds being developed for potential antiviral and oncology applications. The platform has been explored for pathogenic viruses as well as cancer indications involving brain and pancreatic tumors. Additional related compounds from the WP1122 portfolio have also been selected for externally funded antiviral studies.
Expanded Oncology Collaborations: Moleculin has continued expanding collaborations and investigator-sponsored programs tied to Annamycin and WP1066 across brain tumors, pancreatic cancer, liver cancer, and additional oncology indications through partnerships with research institutions and cancer centers.

The company continues positioning itself around differentiated oncology therapies with multiple regulatory, clinical, and data milestones expected across its pipeline throughout 2026.

Current Milestones Driving Momentum

(MBRX) has continued releasing a steady flow of developments throughout April 2026 as momentum builds across its oncology pipeline:

Pancreatic Cancer Survival Data Presented at AACR 2026: Moleculin announced new preclinical data showing Annamycin extended survival by more than 60% in metastatic pancreatic cancer models while also demonstrating significant tumor volume reduction across multiple PDAC studies. The company highlighted the therapy’s non-cardiotoxic profile as a key differentiator versus traditional anthracyclines.
ASCO 2026 Presentation Accepted: Moleculin announced that new data involving Annamycin was accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the largest oncology conferences globally.
CEO Corner Spotlighted Non-Cardiotoxic Profile: Moleculin recently released another CEO Corner segment emphasizing Annamycin’s differentiated non-cardiotoxic profile, a feature management continues positioning as a major advantage compared to traditional anthracycline chemotherapies.
45-Patient MIRACLE Enrollment Milestone Reached: Earlier this year, Moleculin confirmed enrollment of the 45th patient in its pivotal Phase 2B/3 MIRACLE AML trial, keeping the company on track for a highly anticipated interim data unblinding expected in mid-2026.
Preliminary 40% Remission Signals Reported: The company also disclosed a preliminary blinded composite complete remission (CRc) rate of 40% across the first 30 MIRACLE subjects treated, including a 30% complete remission rate.
Global Clinical Expansion Continues: Moleculin has continued expanding clinical activity internationally while advancing additional collaborations and investigator-sponsored studies tied to Annamycin and WP1066 across multiple oncology indications.

7 Factors Putting (Nasdaq: MBRX) On Our Watchlist — Friday, May 8, 2026

1. Ultra-Low Float Structure: (MBRX) continues trending with fewer than 6M shares in the public float, creating a tightly held setup that can react sharply as attention and volume increase.

2. Mid-2026 MIRACLE Trial Data Readout Approaching: The company recently confirmed that the highly anticipated 45-patient interim unblinding from its pivotal MIRACLE Phase 2B/3 AML trial remains on track for mid-2026.

3. Enrollment Milestone Officially Reached: In March 2026, Moleculin announced enrollment of the 45th patient in the MIRACLE trial, triggering the final countdown toward interim data analysis.

4. Encouraging Early Efficacy Signals: The company reported a preliminary blinded composite complete remission (CRc) rate of 40% across the first 30 MIRACLE subjects treated, including a 30% complete remission rate.

5. Phase 3 AML Program Continues Advancing Globally: MIRACLE remains a pivotal adaptive Phase 2B/3 global study evaluating Annamycin plus cytarabine in relapsed/refractory AML, with enrollment spanning multiple countries and sites.

6. Differentiated Safety Profile: Annamycin continues standing out for its lack of observed cardiotoxicity, a major limitation associated with traditional anthracyclines. Independent review data now spans more than 90 treated subjects.

7. Multiple Regulatory & Pipeline Potential Catalysts Ahead: Alongside its AML program, Moleculin continues advancing additional oncology initiatives while maintaining FDA Fast Track and Orphan dr-ug designations tied to portions of its pipeline, keeping several potential catalysts on the horizon.

Take A Look At (Nasdaq: MBRX) Right Now…

When you step back and look at the broader picture, (MBRX) is beginning to bring together several elements that tend to attract attention in the oncology space at the same time.

The company continues operating with a public float of fewer than 6M shares while advancing a late-stage AML program toward a highly anticipated mid-2026 interim MIRACLE data unblinding. At the same time, analyst targets currently ranging from $20 to $31 imply substantial upside potential from recent levels. Momentum across the pipeline has also continued building in recent weeks.

Add in FDA Fast Track and Orphan Dr-ug designations, expanding international clinical activity, and additional collaborations tied to multiple oncology indications, and the setup begins to stand out across several fronts simultaneously.

Taken together, this is the type of story that can start drawing broader visibility as milestones approach.

We’ll be watching (MBRX) closely this morning—Friday, May 8, 2026.

Take a closer look while it’s still early.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 05/08/2026 and ending on 05/08/2026 to publicly disseminate information about (MBRX:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Source Coastal Media LLC has been paid thirty one thousand five hundred USD (“Funds”). These Funds were part of the thirty five thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (MBRX:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/mbrx-e3eUW/#details}